Electrochemical sensitive detection of amyloid-β oligomer harnessing cellular prion protein on AuNPs embedded poly (pyrrole-3-carboxylic acid) matrix

Zhao, Chen; Wang, Audrey; Tang, Xiaoying; Qin, Jieling

doi:10.1016/j.mtadv.2022.100250

Cited by 14 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, this approach is compared with other published articles involving label-free electrochemical assays for Aβ oligomer detection which use different immobilization systems such as AuNPs, monolayers, polymers, or composites, among others (Table S1). In most of the reports, the determination of the oligomer is carried out in a cell conditioned medium, artificial, or enriched biological fluids, , and only one work analyzed the real plasma samples of AD patients . The present work provides an analysis of clinically relevant complex samples of AD patients such as brain tissue, CSF, and plasma.…”

Section: Resultsmentioning

confidence: 99%

Gold Nanoparticle-Decorated Catalytic Micromotor-Based Aptassay for Rapid Electrochemical Label-Free Amyloid-β42 Oligomer Determination in Clinical Samples from Alzheimer’s Patients

Gallo-Orive,

Moreno-Guzmán,

Sanchez-Paniagua

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

Micromotor (MM) technology offers a valuable and smart on-the-move biosensing microscale approach in clinical settings where sample availability is scarce in the case of Alzheimer's disease (AD). Soluble amyloid-β protein oligomers (AβO) (mainly AβO 42 ) that circulate in biological fluids have been recognized as a molecular biomarker and therapeutic target of AD due to their high toxicity, and they are correlated much more strongly with AD compared to the insoluble Aβ monomers. A graphene oxide (GO)−gold nanoparticles (AuNPs)/nickel (Ni)/ platinum nanoparticles (PtNPs) micromotors (MM GO−AuNPs )based electrochemical label-free aptassay is proposed for sensitive, accurate, and rapid determination of AβO 42 in complex clinical samples such as brain tissue, cerebrospinal fluid (CSF), and plasma from AD patients. An approach that implies the in situ formation of AuNPs on the GO external layer of tubular MM in only one step during MM electrosynthesis was performed (MM GO−AuNPs ). The AβO 42 specific thiolated-aptamer (Apt AβOd 42 ) was immobilized in the MM GO−AuNPs via Au−S interaction, allowing for the selective recognition of the AβO 42 (MM GO−AuNPs −Apt AβOd 42 −AβO 42 ). AuNPs were smartly used not only to covalently bind a specific thiolated-aptamer for the design of a label-free electrochemical aptassay but also to improve the final MM propulsion performance due to their catalytic activity (approximately 2.0× speed). This on-the-move bioplatform provided a fast (5 min), selective, precise (RSD < 8%), and accurate quantification of AβO 42 (recoveries 94−102%) with excellent sensitivity (LOD = 0.10 pg mL −1 ) and wide linear range (0.5−500 pg mL −1 ) in ultralow volumes of the clinical sample of AD patients (5 μL), without any dilution. Remarkably, our MM-based bioplatform demonstrated the competitiveness for the determination of AβO 42 in the target samples against the dot blot analysis, which requires more than 14 h to provide qualitative results only. It is also important to highlight its applicability to the potential analysis of liquid biopsies as plasma and CSF samples, improving the reliability of the diagnosis given the heterogeneity and temporal complexity of neurodegenerative diseases. The excellent results obtained demonstrate the analytical potency of our approach as a future tool for clinical/POCT (Point-of-care testing) routine scenarios.

show abstract

Section: Resultsmentioning

confidence: 99%

Gold Nanoparticle-Decorated Catalytic Micromotor-Based Aptassay for Rapid Electrochemical Label-Free Amyloid-β42 Oligomer Determination in Clinical Samples from Alzheimer’s Patients

Gallo-Orive,

Moreno-Guzmán,

Sanchez-Paniagua

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

show abstract

“…92 Based on these findings, several electrochemical probes were reported for the selective detection of AβOs by using PrP C (95-110) as a recognition moiety. [93][94][95][96] For example, the peptide PrP C (95-110) was decorated on the surface of an electrode through a conductive linker to recognize AβOs in the biofluids (Fig. 3A).…”

Section: Reviewmentioning

confidence: 99%

Recent developments in the chemical biology of amyloid-β oligomer targeting

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Multi-sensor-based intelligent home monitoring or wearable devices able to track body functions relevant for ND prognosis seem to be the future trend in wellbeing and mental healthcare. More elaborated immunoassays are reported for electrochemiluminescence [113] or electrochemical [114,115] ultralow ex vivo Aβ or prion protein detection (from 0.1 ng/mL up to nanomolar levels) and for SERS detection below fM concentrations for the tau protein [109].…”

Section: Sers Biosensors Developed For Proteinopathiesmentioning

confidence: 99%

A Review on Integrated ZnO-Based SERS Biosensors and Their Potential in Detecting Biomarkers of Neurodegenerative Diseases

et al. 2023

View full text Add to dashboard Cite

Surface-enhanced Raman spectroscopy (SERS) applications in clinical diagnosis and spectral pathology are increasing due to the potential of the technique to bio-barcode incipient and differential diseases via real-time monitoring of biomarkers in fluids and in real-time via biomolecular fingerprinting. Additionally, the rapid advancements in micro/nanotechnology have a visible influence in all aspects of science and life. The miniaturization and enhanced properties of materials at the micro/nanoscale transcended the confines of the laboratory and are revolutionizing domains such as electronics, optics, medicine, and environmental science. The societal and technological impact of SERS biosensing by using semiconductor-based nanostructured smart substrates will be huge once minor technical pitfalls are solved. Herein, challenges in clinical routine testing are addressed in order to understand the context of how SERS can perform in real, in vivo sampling and bioassays for early neurodegenerative disease (ND) diagnosis. The main interest in translating SERS into clinical practice is reinforced by the practical advantages: portability of the designed setups, versatility in using nanomaterials of various matter and costs, readiness, and reliability. As we will present in this review, in the frame of technology readiness levels (TRL), the current maturity reached by semiconductor-based SERS biosensors, in particular that of zinc oxide (ZnO)-based hybrid SERS substrates, is situated at the development level TRL 6 (out of 9 levels). Three-dimensional, multilayered SERS substrates that provide additional plasmonic hot spots in the z-axis are of key importance in designing highly performant SERS biosensors for the detection of ND biomarkers.

show abstract

Electrochemical sensitive detection of amyloid-β oligomer harnessing cellular prion protein on AuNPs embedded poly (pyrrole-3-carboxylic acid) matrix

Cited by 14 publications

References 39 publications

Gold Nanoparticle-Decorated Catalytic Micromotor-Based Aptassay for Rapid Electrochemical Label-Free Amyloid-β42 Oligomer Determination in Clinical Samples from Alzheimer’s Patients

Gold Nanoparticle-Decorated Catalytic Micromotor-Based Aptassay for Rapid Electrochemical Label-Free Amyloid-β42 Oligomer Determination in Clinical Samples from Alzheimer’s Patients

Recent developments in the chemical biology of amyloid-β oligomer targeting

A Review on Integrated ZnO-Based SERS Biosensors and Their Potential in Detecting Biomarkers of Neurodegenerative Diseases

Contact Info

Product

Resources

About